Study #2020-1059
Phase I Study of Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients with Relapse Refractory Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Belantamab mafodotin
Description
The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after transplant will also be studied
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase I
Physician name:
Neeraj Saini
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.